RESUMO
The recent development of 225Ac-PSMA617 for therapy of prostate cancer has strikingly demonstrated the clinical potential of targeted alpha therapy. Further promising applications of the alpha emitters 225Actinium and its daughter nuclide 213Bismuth include the therapy of brain tumors, bladder cancer, neuroendocrine tumors, and leukemia. This paper will provide a brief overview on the current status of the clinical development of compounds labelled with 225Ac or 213Bi and describe the various production routes that are in place or are under development to meet the increasing demand for these radionuclides.
Assuntos
Actínio/provisão & distribuição , Actínio/uso terapêutico , Bismuto/provisão & distribuição , Bismuto/uso terapêutico , Radioisótopos/provisão & distribuição , Radioisótopos/uso terapêutico , Humanos , Marcação por Isótopo , Masculino , Neoplasias da Próstata/radioterapiaRESUMO
This talk briefly reviews the earlier work in the field and highlights the contributions of colleagues whose clear vision paved the road for success of TAT. The talk primarily will focus on the development of the radioisotopes for application in TAT. The challenges regarding release of daughter radioisotopes will be briefly discussed, and a summary of the alternative approaches for production of 225Ac will be presented.
